A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Active, not recruiting · Phase 3 · NCT05508789
Conditions: Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
At a glance
- Research payments reported, 2025
- $160,810
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 1,500
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Donanemab (drug), Placebo (drug)
- Dates
- Started 2022-10-10; completion 2028-07
- Results posted
- Not yet
The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.
From ClinicalTrials.gov, last updated 2026-09-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $160,810 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $160,810
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.